TOP2A and breast carcinoma: In this study, the pathology and survival data of a large cohort of patients with high-risk primary breast cancer were reanalysed (Rodenhuis et al, 2003; Rodenhuis et al, 2006) We retrospectively studied the association of the molecular subtyping of breast cancer based on IHC with treatment outcome and we investigated a possible influence of the anthracycline dose on treatment effect for tumours with a TOP2A amplification.